Shumway Capital

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Artsy is the world’s largest online art marketplace. Browse over 1 million artworks by iconic and emerging artists from 4000+ galleries and top auction houses.